Optimizing Outcomes in HR+/HER2-Metastatic Breast Cancer: Molecular Testing and Targeted Strategies - Episode 8

The Evolving Landscape of mBC Treatment: Unmet Needs and Future Predictions

,

EP. 1: Clinical Perspectives on Biomarker Testing in mBC
EP. 2: Repeat Biomarker Testing in mBC: Navigating the Rapidly Evolving Treatment Landscape
EP. 3: Selecting the Optimal CDK4/6 Regimen for First-Line Therapy
EP. 4: Clinical Considerations for CDK4/6 Inhibition Beyond Progression
EP. 5: Expert Insights: Managing Patients with PIK3CA Mutations
EP. 6: Navigating Treatment Selection in Patients with Both ESR1 and PIK3CA Mutations and Expert Perspective for Integrating Oral SERDs into Clinical Practice
EP. 7: The Emerging Role of Triplet Therapy in mBC: Opportunities and Challenges
Now Viewing
EP. 8: The Evolving Landscape of mBC Treatment: Unmet Needs and Future Predictions

Video content above is prompted by the following:

  • Dr. Conlin to Dr. O’Shaughnessy: Looking ahead, how do you see the treatment landscape evolving?
    • What impact might the SERENA-6 trial have on sequencing practices (Turner et al. Future Oncology 2023)?
    • What mechanisms of resistance to PI3K/AKT pathway inhibitors or oral SERDs do you anticipate?
    • What unmet needs remain to be addressed?

Related Content:

Optimizing Outcomes in HR+/HER2-Metastatic Breast Cancer: Molecular Testing and Targeted Strategies